All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the 2022 ASCO Annual Meeting, the AML Hub spoke with Curtis Lachowiez, MD Anderson Cancer Center, Houston, US. We asked for an update on triplet therapy with ivosidenib, venetoclax, and azacitidine.
Update on triplet therapy with ivosidenib, venetoclax, and azacitidine.
In this video, Lachowiez discusses an updated analysis of the completed phase Ib portion of the study of ivosidenib combined with venetoclax, either with/without azacitidine, presented at ASCO 2022. Lachowiez outlines the study design and enrollment criteria, then goes on to discuss adverse effects and response rates for the different patient groups. Finally, Lachowiez describes findings on IDH-1 clearance rates, overall survival, MRD, and the upcoming phase II expansion cohorts.
2022 ELN recommendations for the management of AML in adults
A summary of the updated guidelines for the management of AML, from the same publication in Blood, by Döhner et al. on behalf of the ELN.
Treatment of older or unfit patients with AML
Prof. Courtney DiNardo, MD Anderson Cancer Center, Houston, US, discussed the optimal treatment strategy for elderly or frail patients with AML at the 1st NCRI AML academy.
Subscribe to get the best content related to AML delivered to your inbox